News summarySEC EDGARNov 3, 2026, 12:00 PM
Madrigal Pharmaceuticals, 8-K (2.02, 9.01): reported results of operations
Madrigal reported third-quarter 2026 revenue of $431.3 million, up 50% year over year, Rezdiffra year-to-date sales of $1.1 billion, and its first profitable quarter; it also reported $961.8 million in cash and securities and plans a Phase 3 trial expected to enroll over 2,000 patients.